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LOCALIZED BILIARY ISCHEMIA IN PATIENTS WITH HEPATIC
ARTERIOVENOUS MALFORMATIONS, A NEWLY RECOGNIZED SYNDROME
OCCURING IN HEREDITARY HEMORRHAGIC TELANGIECTASIA: DIAGNOSIS
AND MANAGEMENT
Rasha S. Khoury, Guadalupe Garcia-Tsao, Lawrence H. Young, Katharine J. Henderson,
Robert I. White, Jr. Yale Vascular Malformation Center, Yale University School of
Medicine, New Haven, CT.
The clinical manifestations of hepatic arteriovenous malformations
(HAVMs) were elucidated.
A review of the literature was undertaken to better understand how HAVMs
specifically affect the biliary system. A retrospective review of the 50 patients with
HAVMs seen at the Yale University HHT Center was done, including clinical
manifestation, intervention and outcome analysis.
Of 50 adults with HAVM, median age was 64 (range 17-73) and 84% were
female. Initially 74% were classified as Type 1, symptomatic heart failure, 16% as Type
2, portal hypertension, and 10% as Type 3, biliary abnormalities. In Type 1 conversion to
Type 3 was associated with the highest mortality and in Type 3 invasive procedures
precipitated rapid decline and need for transplant +/- death. Of the Type 3s, case reports
of two sisters with localized biliary ischemia were presented.
To our knowledge this is the first description of localized biliary HHT involvement,
diagnosis and management.
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1
Introduction
Hereditary Hemorrhagic Telangiectasia (HHT), Osler-Weber-Rendu, is an
autosomal dominant disease with variable penetrence characterized by vascular
malformations. First described in 1896 by Rendu who recognized the disease as local
vascular “incompetence” and recommended applying tannin to control the bleeding
associated with it (1) then by Osler in 1901 (2) and Weber in 1907 (3) who described the
disease as inherited “vessel inadequacy” rather than a bleeding dyscrasia. When in 1909
Hanes (4) described the dilated vessels without muscular and connective tissue layers
under light microscopy he suggested the term Hereditary Hemorrhagic Telangiectasia
(HHT) which encompassed the main features of the disorder recognized at that time.
Our contemporary understanding of HHT histopathology builds on Hanes’ light
microscopy work, demonstrating local dilations of the venules post capillary beds with
stress fibers in the cells along the lumen border in the developing telangiectases (5).
When these young telangiectases mature the venules dilate significantly and become
twisted with excess smooth muscle layers and no elastic fibers. The Yale-HHT center and
others view these changes as secondary to the absence of capillaries and direct arteriolevenule connections. On a microscopic scale these telangiectases can be superficial,
cutaneous or mucocutaneous, and visible to the naked eye when affecting the hands, face
and torso. These areas of directly connected arteries and veins without capillary beds,
when large, form the characteristic arteriovenous malformations (AVMs) that appear
viscerally throughout multiple systems such as the lungs, brain and liver (6).
The clinical diagnosis of HHT is based on the Curaçao criteria (7). These criteria
include epistaxis, telangiectases at characteristic sites (lips, mouth, fingers, nose), visceral
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involvement (GI lesions, or lung, brain, liver AVMs) and a first-degree relative with
HHT. Inheritance is autosomal dominant with variable penetrance and affects men and
women of all ages and ethnic backgrounds (8). About 10-20 in 100,000 individuals
worldwide are affected by HHT (9-12) and 1 in 5-8000 in Dakeishi et al (8), with varying
manifestations even within the same family. Genetic studies have established HHT as the
first human disease defined by a mutation in a member of the (TGF)-β receptor complex.
Nearly all patients and families affected by HHT fall into the HHT categories HHT-1 and
HHT-2 in reference to mutations mapped to two genes (ENG- endoglin mapped to
chromosome 9 (13) and ACVRL1 or ALK-1 mapped to chromosome 12 (14, 15), both
belong to the transforming growth factor (TGF)-β receptor superfamily (16). Though the
exact mechanism of genetic-vascular-pathology of HHT is not completely understood we
do know that (TGF)-β superfamily affects vascular biology through membrane receptors,
type I and type II serine/threonine kinases. Once a ligand binds type II receptors, with
which the homodimeric membrane protein ENG functions in association, as an auxiliary
receptor, they recruit and phosphorylate type I receptors (ALK-1) phosphorylating
SMAD proteins and eventually modulating gene transcription by initiating the signaling
cascade. HHT is thought to be the result of ENG and ALK-1 haploinsufficiency. Saxena
et al (17) suggest that the lack of endoglin may result in the failure to initiate production
of extracellular matrix by TGF-beta leading to failure of vascular remodeling and a
haphazard arrangement of abnormal telangiectatic vessels.
With variable penetrance the clinical manifestations of HHT are age related, GI
and hepatic involvement more prevalent in older patients for example (18), epistaxis
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more likely to present in childhood. The genotype-phenotype relationship in HHT has
been studied in the last decade and confirmed some clinically noted differences in
phenotype distribution based on sex. Studies using genetic sequencing have demonstrated
specific variability with respect to gender and subtype, highlighting a predominance of
PAVMs (19-21) and HAVMs (21-24) in female patients as well as linking PAVMs with
symptomatic HHT-type 1 and HAVM with HHT-type 2. In late 2003 genetic testing for
HHT became available, allowing families and providers to test multiple individuals
within an affected family. The ability to genotype a family is especially useful in children
who have not yet become symptomatic but where early screening and intervention can
reduce/prevent catastrophic sequelae. Since the mutation is family specific, affected
asymptomatic family members are readily detected and can undergo brain and lung
screening. In the case of families with liver involvement, genetic testing may help us
identify those individuals that need more careful and less invasive evaluation when
presenting with abdominal or RUQ pain or other biliary symptoms.
Clinically HHT manifests with epistaxis in 93% of patients secondary to
telangiectases in the nasal mucosa (25). Nosebleeds vary in severity and frequency but
onset is mostly in the first two decades of life. 13-44% of patients experience GI bleeding
secondary to telangiectases of the stomach and small intestine, these also vary in severity
and frequency but onset is usually in the 5th and 6th decades (26, 27). Organ system
involvement includes the brain, lungs and liver. CAVM has been reported in 10-23% of
HHT patients (28, 29) with a rate of cerebral hemorrhage comparable to non-HHT
CAVM population (30). PAVMs are a more variable manifestation that can occur at any
point in a patient’s life. HHT patients with PAVMs can have single discrete lesions,
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multiple discrete lesions or diffuse involvement. PAVMs affect 24%-60% (31-34) of
HHT patients and can present with cyanosis, clubbing, dyspnea on exertion and
hypoxemia. The treatment of choice for symptomatic PAVMs currently is transcatheter
embolotherapy in adults (20, 35-37).
By far the most common visceral HHT involvement, albeit asymptomatic, is the
hepatobiliary system. Large prospective studies using non-invasive imaging have shown
HAVMs occur in 48% (38) and 73% (39, 40) of HHT patients with symptoms appearing
in about 8%-31% (10, 38, 39). With the evolution and use of non-invasive imaging
modalities we are likely to diagnose even more patients with liver involvement.
Historically (41) liver involvement was broken down by histologic group: 1)
telangiectasia with fibrosis or cirrhosis; 2) cirrhosis without telangiectasia (cirrhosis was
thought to be related to superimposed liver disease, e.g. post transfusion hepatitis) and 3)
telangiectasia without fibrosis or cirrhosis. Today we understand liver involvement in
HHT to be arteriovenous malformations (AVMs) that lead to various forms of shunting:
hepatic artery to hepatic vein (Figure 1A), hepatic artery to portal vein (Figure 1B) and
portal vein to hepatic vein (Figure 1C). Garcia-Tsao (42) describes these three shunt
types as likely occurring simultaneously with singular and likely alternating functional
predomination. These shunts lead to the various symptoms characteristic of hepatic
involvement: high output cardiac failure (Type 1), portal hypertension (Type 2) and
biliary ischemia (Type 3). Symptoms appear to be more common in women than men
with onset in the third decade of life. They also have the capacity to occur, exacerbate
and remit spontaneously, as evidenced by symptom variation depending on circulatory
state as in pregnancy, anemia, atrial fibrillation, etc. Most commonly patients present

5
with signs and symptoms of high output cardiac failure (shortness of breath and edema
without evidence for PAVM or anemia) with fewer patients presenting with portal
hypertension (PHT) (ascites, variceal hemorrhage, abdominal pain) and fewer still
presenting with biliary symptoms (abdominal pain, cholangitis, encephalopathy).
Symptoms can begin with RUQ pain that brings a patient to their provider where hepato
or hepatosplenmegaly can be found, a RUQ bruit (or thrill) +/- ascites. Laboratory testing
may reveal elevated alkaline phosphatase and GGT, anicteric cholestasis, present in 73%
of patients (42, 43). Also –but rare- the following presentations may occur: portosystemic encephalopathy, abdominal angina and nodular regenerative and focal nodular
hyperplasia (44, 45) the latter which can lead to misdiagnosis of cirrhosis, more
accurately pseudocirrhosis (46) as well as a misdiagnosis of HCC (47).
Various imaging modalities are useful in the diagnosis of hepatic involvement
when a patient is symptomatic but otherwise screening is not recommended given the
high prevalence of asymptomatic liver involvement in the HHT population and the
tendency for unfamiliar providers to pursue the imaging pathology with invasive
procedures that can lead to unfavorable consequences. The gold standard for the
diagnosis of HAVM is angiography (48) but the more commonly used and (preferred)
non-invasive tests are ultrasonography and CT. Wu (49) showed that arteriovenous
shunting and arterioportal shunting can be demonstrated by early/differential
enhancement of hepatic veins and portal veins respectively with multidetector CT but
also showed that these findings do not necessarily correlate with clinical presentation.
The authors found biliary pathology on imaging more prevalent in symptomatic patients
compared to asymptomatic patients without displaying biliary symptoms clinically which
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Garcia-Tsao et al suggest may be due to an increase in shunting and biliary ischemia
further along the time course of liver involvement in HHT. While there is a gold standard
for diagnosis of HAVM, there is no predictable course of complications or gold standard
for treatment. Consensus recommendations are (50) to aggressively treat symptoms such
as heart failure and pulmonary hypertension but also to be conservative with invasive
liver procedures (avoiding liver biopsy, ERCP and refraining from the past practice of
hepatic artery embolization as a means to control high flow states).
Albeit the least common, the biliary subgroup (Type 3) of HHT hepatic
involvement can be particularly aggressive and unpredictable. The patients are at risk for
rapidly progressive hepatic failure but outcome can be improved with greater recognition
of the disease process and heightened awareness of the clinical, imaging and biochemical
presentation of the disease as well as the options for management and definitive
treatment. This study reports 2 sisters with HHT and HAVM who presented with
“spontaneous localized biliary ischemia”, a unique syndrome. Conservative management
including percutaneous biliary drainage led to resolution of symptoms. This localized
form of symptomatic biliary ischemia is contrasted with the its more generalized form.

Statement of Purpose and Hypothesis
The purpose of this thesis is multifold. A review of the English literature was
preformed to better understand and define the biliary subtype of liver involvement in
HHT. A retrospective analysis of patients seen at the Yale University HHT Center was
done, including clinical manifestation, intervention and outcome analysis. Case reports
are presented of two sisters in their third decade with hepatic HHT involvement

7
presenting with localized biliary ischemia. To our knowledge this is the first description
of localized biliary HHT involvement. These results, with a recommendation on
diagnosis and management of localized biliary ischemia in HHT patients are presented
here.

Subjects and Methods
A. Literature Review
All case reports of patients with biliary symptoms secondary to hepatic AVMs
were searched using Medline. Reports prior to 1950 were found by researching
references of reviews and reports published after 1950. Only reports in the English
language were included. Reports were reviewed and the following data collected: age,
gender, presenting symptom (RUQ/abdominal pain; cholangitis/jaundice;
nausea/vomiting; weight loss; other including shortness of breath; liver bruit; lab
abnormalities (alkaline phosphatase; bilirubin;; biliary abnormality on imaging),
intervention preformed, and outcome. This discussion will focus on those with HHT liver
involvement Type 3 presenting with RUQ pain.
B. Chart Review
The charts of patients seen and evaluated at the Yale-HHT center in the last 20
years with a diagnosis of liver involvement were reviewed with the approval of the Yale
Human Investigation Committee.
The unique presentation of localized biliary ischemia in two patients at the YaleHHT center will be presented in case report with a discussion on diagnosis and
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management. To our knowledge this is the first time this presentation has been
recognized prospectively.

Results
In the last 12 years, of the 2500 patients evaluated at the Yale-HHT center, 50
presented with or developed symptoms related to liver involvement. The median age at
initial evaluation was 64 years (range 17-73) years and 42/50 (84%) were women.
Patients were initially classified into Type 1, symptomatic high cardiac output state
(37/50 patients, 74%), Type 2, portal hypertension (8/50 patients, 16%), and Type 3,
biliary abnormalities (5/50 patients, 10%) [Young, Garcia, White et al. unpublished data].
Of the type 1 patients, 4 went on to develop biliary ischemia in their final year of life,
these are classified as type 1 to type 3 converters and overall had the highest mortality.
The focus of this thesis will be the Type 3 group, of whom 100% were female, median
age was 39 years (range 31-59). Type 1 and 2 patients were treated medically to either
correct or control symptoms: anemia, dyspnea, edema and prevent recurrent atrial
fibrillation. Type 3 patients were treated aggressively with antibiotics when infection
was suspected and those with biliary pain were given frequent small meals and bile salts
as well as analgesics. Two of the Type 3 patients were treated with percutaneous drainage
of focal bile collections with excellent outcome, case reports highlighted below. During
mean follow-up of 4.8 years, 17/50 (34%) of patients died. In Type 1 patients, 10/37 died
at a median of 4 years after initial evaluation due to spontaneous biliary duct necrosis
and/or liver hemorrhage (4) of whom 3 converted from type 1 to type 3 in the final year
of life, right heart failure with superimposed complications (4), liver necrosis post hepatic
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artery embolization (1) and unknown (1). In Type 2 patients, 6/8 died at a median of 4
years due to esophageal varices (1), intractable bleeding from gastrointestinal
telangiectases (2), presumed pulmonary emboli (1), pancreatic cancer (1), and lung
cancer (1). One of three Type 3 patients died after failed liver transplantation.
The Yale-HHT center has previously presented the largest study on hepatic HHT
involvement and noted that progressive disease leading to mortality is frequent but not
universal. In that study, Type 1 patients with intractable heart failure who went on to
devastating biliary ischemia and necrosis, patient # 3, 4 and 5, had the highest mortality
rate. Table 1 illustrates the 3 patients presenting with Type 3 as it had been described up
to 2005, and the 3 patients who converted from Type 1 to Type 3 as a final scenario. P1
and P2 are our cases of localized biliary ischemia. All 8 patients presented with RUQ
pain apparently precipitated by various types of inflammatory biliary episodes.
Note: P7’s sister died at age 29 of Type 3 HHT shortly after OLT for biliary necrosis at
an outside hospital (OSH). She initially presented with RUQ pain to OSH where a
cholecystectomy was done revealing gangrenous cholecystitis, post-operative
complications included persistent sepsis and cholangitis. Initial imaging showed normal
caliber bile ducts but quickly developed communicating intrahepatic abscesses with the
biliary tree, the patient was transferred to transplant center for evaluation and received
OLT but died 2 weeks later as a result of sepsis. Providers attributed her disease process
to a cholangitis rather than a Caroli’s variant. The liver explant had multiple areas of
focal centrilobular necrosis but relatively well preserved and unremarkable vasculature
and bile ducts.
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Table 2 illustrates the 14 cases reported in the literature of HHT patients with
hepatic involvement Type 3. 100% of the patients were female with an age range of 2662 and a median of 38 years. 11/14 patients presented with RUQ or abdominal pain, 7/14
with jaundice or cholangitis, 4/14 with nausea/vomiting and weight loss, 4/14 with fever
and 1/14 with hemobilia. In 2/14 the authors reported the presence of a liver bruit. 10/14
presented with alkaline phosphatase abnormalities and 11/14 with abnormal biliary
imaging. The range of time of onset to outcome was 6 hours-15 months with a mean of
5.7 months. Most patients progressed to bacteremia, severe liver function abnormalities
and diffuse bile leaks/hepatic abscesses. 11/14 received liver transplant as a definitive
treatment for liver failure or imminent failure with excellent outcome. 2 of the 14 died,
one of severe and fulminant biliary sepsis (6 hours after onset of pain) and one after
hepatic artery ligation and bile leak progression.

Case Reports of Yale HHT patients with focal Type 3 liver involvement

WM: A 39 year-old woman diagnosed with HHT at age 21, from an HHT family
with unique liver involvement (sister presented below), began experiencing abdominal
pain in August 2006. The pain began in the epigastrium radiating to the RUQ and
localized to the RUQ by November 2006. The pain was sharp and unrelated to eating or
activity but it did awaken WM at night. It remained manageable until December 2006
when WM presented with severe RUQ pain and mild elevation of liver enzymes
(AST/ALT 46/53 and alkaline phosphatase, AP, 72); all other biochemical data was
within normal range. On abdominal CT (Figure 2a) the liver had heterogeneous uptake,
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particularly in the posterior right lobe. There was no evidence of hepatomegaly or
intrahepatic cysts, and no enlargement of the IVC or the hepatic veins. The posterior right
lobe of the liver showed a decreased vascular pattern and low attenuation density
(diffuse, involving 25-30% of the posterior right lobe) consistent with AVM and
ischemia within the liver parenchyma.
By January 2007, the pain became more of a constant discomfort, and WM reported the
emergence of the following symptoms: a “racing” heart, shortness of breath, and
orthopnea. At that time there were no signs or symptoms of ascites, edema, GI bleeding
or encephalopathy. On exam WM had scattered telangiectases but no jaundice. She was
normotensive (BP 120/80) with a normal heart rate (88), in contrast to patients with Type
1 hepatic involvement patients who present with wide pulse pressure and large volume
pulse. Abdominal exam was notable only for a clear bruit over the liver and particularly
in the epigastrium. Laboratory data included: AST/ALT 41/23 and AP 86 (GGT 68).
Contrast cardiac echo indicated mild shunt and CT without contrast demonstrated several
small PAVMs that did not need treatment at that time. WM was diagnosed with HHT
liver involvement and abdominal pain was attributed to biliary ischemia (Type 3) with
clinical severity unaccounted for by biochemical data and imaging. Wu et al (49) had
previously demonstrated that imaging findings are not predictive of clinical severity in
most patients with liver HHT.
At this point it was felt that WM’s liver involvement was relatively minor requiring no
intervention and would hopefully resolve spontaneously. Were it to continue or get
worse, it was recommended WM return to our Center for evaluation and treatment.
In May 2007, WM presented to her local hospital with uncontrollable RUQ pain. A
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HIDA scan showed a low gallbladder EF of 21% (suggesting chronic cholecystitis with
biliary dyskinesia but without evidence of acute cholecystitis or common bile duct
obstruction). One week later abdominal CTA showed a diffusely abnormal liver with
multiple enhancing foci throughout both the right and left hepatic lobes likely related to
small telangiectases (as described in Garcia et al 2007 the markedly heterogeneous
hepatic enhancement pattern of symptomatic HHT involvement). Also seen at this time
was a new 3cm (3.0 x 2.1) cyst in the right posterior hepatic lobe with a subcentimeter
cyst in the inferior right hepatic lobe. In attempt to continue non-invasive management
and minimize complications, WM was placed on a regimen of antibiotics, bile salts and
analgesics. Her pain continued to be intermittent but severe, lasting 24-36 hours at a time
and she was without fever.
In late June her pain became refractory to the pain regimen, and evolved to
continuous throbbing RUQ pain accompanied by low-grade fever. WM was admitted to
YNHH and found to have elevated AST/ALT (51/23) and AP (269), her total/direct
bilirubin never rose above normal range. Abdominal CTA showed a diffusely abnormal
enlarged liver with small vessel AV shunting and a prominent biloma, with no evidence
of infarction. Given improving pain control and lack of infection or infarction signs WM
was continued on an adequate pain regimen and discharged with outpatient follow-up on
HD 7. At the time of discharge AST/ALT 28/19 and AP was 108.
One week later WM was readmitted to the liver service with refractory and
worsening RUQ pain, fever and chills. AST/ALT were found to be elevated at 141/115,
alkaline phosphatase at 149, and all other biochemical data were within normal range. A
repeat abdominal CT (Figure 2b) revealed an enlarging fluid filled lesion in the right
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hepatic lobe with a question of infection given the clinical presentation. Meanwhile,
transaminases climbed to 154/123 and AP reached 188. It was felt that aspiration and
drainage by IR would be beneficial, although we remained concerned about draining the
cyst since our previous experience suggested worsening liver function after intervention
(Table 1, patients # 3 and 6). We did not appreciate at the time that this may have been a
more localized process than we and others had seen previously. On HD 3 the collection
was aspirated and found to be sterile. Due to continued pain and fever on HD 5 a second
abdominal CT with oral and IV contrast (Figure 2c) was obtained and showed interval
increase in the right hepatic lobe fluid collections. On HD 7, due to concern for an
abscess and realization that until we drained this biloma WM could not be weaned from
PCA and would possibly not recover, IR drained the collection and placed a percutaneous
biliary drain (Figure 2d, 2e). WM’s pain began to resolve slowly and she was discharged
on HD 10 (AST and ALT 23/28 and AP 116 at discharge) with outpatient follow-up, pain
regimen and directions for drain self-care. In subsequent months WM suffered a number
of episodes of bacteremia secondary to tube change/manipulation but did well with
marked reduction in biloma size (Figure 2f-h) and resolution drain output and pain. The
tube was capped and removed 3 months after placement. At 3 month follow-up WM
remains asymptomatic.
Interestingly WM’s sister (EM) presented with a similar clinical picture, at age
31, to an outside hospital. EM is a woman with HHT diagnosed at age 12 in the setting of
childhood nosebleeds, never requiring transfusion, and a positive family history for HHT
including her two sisters, mother and maternal grandmother. At that time EM did not
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have known visceral involvement and her family history specifically did not include
known liver involvement at that point.
EM presented in August 2005 with new abdominal pain which was described as
band-like in the upper abdomen, dull at first but became sharp during the ensuing months.
EM reported having this pain with her two pregnancies in the past, in both cases it
resolved spontaneously. On physical exam EM had multiple mucocutaneous
telangiectases but no jaundice. Cardiopulmonary exam was unremarkable at that time.
Abdominal exam revealed a bruit in the RUQ but no hepatomegaly, ascites, or peripheral
edema. EM underwent workup for ulcers and gallstones over the next 3 weeks without a
cause identified or pain relief. Abdominal CT revealed a cystic area in the right lobe and
was aspirated in her local hospital. Post aspiration her pain became much worse and she
developed fevers and chills and was transferred to a tertiary care center. ERCP was
performed and demonstrated focal sclerosing cholangitis with post stenotic dilation of the
intrahepatic biliary duct (mostly in the posterior segment of the right hepatic lobe). RUQ
ultrasound revealed a cystic lesion in the posterior segment of the right hepatic lobe
without septation or calcification, and through transmission without solid mass features in
the liver and without intrahepatic dilatation. HIDA scan revealed gallbladder dysfunction
with an EF of 30.1%. Given the clinical picture and unrelenting RUQ pain EM underwent
a laparoscopic cholecystectomy in October 2005. Intra-operative retrograde
cholangiography showed the right and left intrahepatic biliary ducts were normal without
focal stenosis or occlusion. Branches of the right hepatic duct, however, demonstrated
focal stenosis and post stenotic dilation, focal sclerosing cholangitis, consistent with
preoperative imaging. This episode of instrumentation likely led to further bacterial
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seeding. EM’s pain, fevers and nausea persisted, and the clinical team was advised to
transfer to a transplant HHT center. Two weeks following aspiration and
cholecystectomy, as EM’s pain continued to progress (at this point she had lost 30lbs
from decreased intake secondary to pain) and signs of infection led to a diagnosis of liver
abscess, antibiotics were started. Abdominal CT showed two types of low attenuation
changes in the right lobe of the liver: one poorly defined and diffuse (cysts), the other
more focal and discrete (ducts), dilated ducts involving the posterior segment of the right
lobe of the liver with an appearance similar to what was seen pre cholecystectomy. Her
heart was slightly enlarged and a prominent IVC was noted on CT. A percutaneous drain
was placed to drain the collection in the right hepatic lobe and P2 was discharged home
with outpatient follow-up. During follow-up she was admitted for fever spikes following
drain repositioning but overall did well with occasional pain when the catheter was
capped.
At 6-week follow-up, post-contrast CT showed a lobulated 3.2 x 7.7cm fluid
collection in the central aspect of right lobe of liver with a percutaneous drain in place
and duct dilation slightly more inferior in the right lobe of the liver. CXR at that time
revealed cardiomegaly. A brief period of drain occlusion during that admission led to
worsening pain, fevers and chills without evidence for bacteremia but with repeat CT
showing enlargement of several intrahepatic fluid collections surrounding the
percutaneous drain. Over the subsequent few months the fever gradually dissipated and
the drain was scaled down in size until it was extracted in April 2006 (8 months after
initial RUQ pain onset/presentation).
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At one year follow-up in April 2007 EM was well, without symptoms. BP and HR
were within normal range. On exam EM had multiple telangiectases on lips, sublingual,
on chest, back and hands but did not have jaundice. Her lungs were clear. Cardiac exam
revealed a holosystolic murmur in the precordium. Abdominal exam revealed a bruit in
the RUQ but no ascites, hepatomegaly or peripheral edema. Of note, EM’s stool guaiac
was positive. GGT was mildly elevated at 74 (normal range 0-51) with all other
biochemical data within normal range. Cardiac echo at follow-up showed evidence of late
right to left shunting suggesting PAVM. Abdominal CT showed heterogeneous
enhancement on arterial phase consistent with arteriovenous shunts, hepatic artery to
hepatic vein. Low-density area in the posterior segment of the right lobe could represent
interval resolution of a cyst and embolization coils were present. EM’s presentation was
attributed to focal biliary liver involvement by HHT, with localized biliary ischemia
arising secondary to AV shunting and good outcome following percutaneous drainage.

Discussion
Overview of HHT in the liver
The characteristic vascular malformations of HHT of the liver are arteriovenous
shunts involving focal sinusoidal ectasia and aberrant direct communications between
hepatic arterial branches and ectatic sinusoids. Portal venous shunts between portal and
hepatic vein have also been documented by 3-D reconstructions of a human HHT liver
(51). These ectatic, dilated vessels have walls of varying thinness and appear in isolation
or clusters, in normal or aberrant locations as demonstrated in a mouse model of Acvrl
+/- (HHT type 2), the type associated with liver manifestation. Srinivasan et al were able
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to confirm lack of vascular integrity with a Von Willebrand factor (VWf) immunostain
and showed how these vessels can bleed into surrounding mouse liver tissue (52). The
compression and atrophy of adjacent hepatocytes in these areas of vascular malformation
seen in the mouse model were later described in the human HHT liver by Blewitt et al in
a landmark study (53) that changed the thinking of the HHT liver community as I will
discuss below.
HHT hepatic vascular malformations have age-dependent penetrance. Patients can
become symptomatic, usually in the third decade, in the setting of AVM growth or new
high volume states such as anemia and pregnancy. The direct arteriovenous
communications result in a decrease in vascular resistance within the liver. With
decreased hepatic vascular resistance, hepatic blood flow increases and a selfperpetuating cycle is set in motion. Total hepatic blood flow increases, associated with
decreasing hepatic vascular resistance and leads to increased venous return to the rightsided chambers of the heart, increased cardiac output (CO), increased pulmonary artery
and pulmonary capillary wedge pressure. Heart rate can increase secondary to
sympathetic activity and with time blood volume will expand in response to the renalhormonal loop and cause cardiac chamber dilatation as well as hypertrophy. Any state of
volume expansion such as anemia which increases CO and enhances existing shunts by
decreasing blood viscosity (54), will then exacerbate this cycle.
Normally the hepatic artery accounts for 25-30% of afferent blood flow in the
liver, and 45-50% of oxygenation. Branches of the hepatic artery and branches of the
portal vein run in parallel within the portal canals/portal tracts where most of the arterial
blood then enters a plexus of capillaries known as the peribiliary plexus surrounding and
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supplying the bile ducts (before draining into the sinusoids). In HHT, the vascular
malformations within the liver (hepatic artery to hepatic vein, hepatic artery to portal vein
and portal vein to hepatic vein) despite causing vascular “high flow states” carry blood
away from the branches of the hepatic artery (significantly decreasing oxygenation
reaching end arterioles and the peribiliary plexus). This relative (or absolute at the
extreme) bypass of the peribiliary plexus could explain the infarction of portal tracts,
ischemia, stricture and stenosis of bile ducts and eventually the bile cysts, referred to as
bilomas. Bilomas are essentially extrahepatic or intrahepatic bile collections outside the
biliary system and have been reported secondary to: a) trauma (55, 56) (many are
iatrogenic (55) and can occur after intra-abdominal surgery (57-59), ERCP (60),
percutaneous transhepatic cholangiography (55) b) complication of transarterial
embolization (61-63), percutaneous ethanol intratumor injection for HCC (64) c) hepatic
infarction (65, 66) d) gallbladder infection (67) e) biliary stone (68) f) bile duct ischemia
(61) and g) AVM (69). The scenario of peribiliary ischemia that arises with AVM growth
and dynamic shift across the hepatic shunts is therefore one of “poverty amidst plenty”
as described by Saluja and White (70) and others (42, 53, 69).

World experience with liver HHT Type 3
Various models have been proposed to explain biliary ischemia in HHT patients.
The overall incidence of the latter is so rare and scattered across institutions that most
reports involve only one or two cases. The largest case series to date includes 5 patients
with biliary ischemia among 19 HHT patients reported at the Yale-HHT Center (42).
Table 2 illustrates the 14 cases that have been reported in the English-language literature
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from centers other than the Yale-HHT center. One hundred percent of patients reported
are female, with a median age of 38 (range 26-65), and the most common presenting
symptom of abdominal pain and/or abdominal bruit and hepatomegaly (Table 2). The
most common laboratory abnormalities were elevated alkaline phosphatase levels from 210 times the upper limit of normal and the most common imaging abnormalities were
biliary pathology on ultrasound, CT or MRI. These cases span 17 years and reflect the
change in understanding and management of these biliary HHT patients.
In 1990 Ball et al (71) described the first case of hepatolithiasis (soft brown
caliculi in the hepatic ducts with surrounding parenchymal necrosis) in a 62-year-old
female HHT patient with HAVM and rapid death from septic shock. Ball et al proposed
that abnormalities in hepatic blood flow led to hepatic fibrosis and nodular regeneration
and went on to explain (as Mendoza et al suggested in 1995(72)) that nodular
transformation is secondary to large anomalous arteries hyperperfusing portions of the
parenchyma, which in turn causes stenosis and compression of large intrahepatic bile
ducts leading to biliary stasis. Stasis and superimposed infection then precipitate stone
formation (lithiasis).
In 1995, Bauer et al (73) presented the case of a 33-year old woman with HHT
and liver failure requiring transplantation, the liver explant was shown to have bile
stained foci of necrosis centered around portal tracts, with the portal collagenous skeleton
isolated and detached. Bauer et al suggested arterial ischemia secondary to AVM shunts
as an etiology for the portal necrosis and biliary stricture leading to bile stasis and
superinfection. This they compared to portal necrosis and biliary sludge seen in liver
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transplantation where the biliary tree sustains ischemic injury as a consequence of storage
at 4 degrees centigrade (74).
McInroy et al in 1998 (75) presented a 31-year-old woman with recurrent RUQ
pain and fever who underwent invasive diagnostic procedures that precipitated
deteriorating liver function, RUQ syndrome and eventually diffuse hepatic ischemia and
multiple abscesses requiring transplantation. The authors presented the explanted liver
and showed that while the intrahepatic biliary ducts were necrosed the extrahepatic ducts
were maintained, a scenario described by Zajko in liver transplant literature. The authors
attributed this to the difference in blood supply, with the intrahepatic ducts being supplied
by the hepatic artery which is vulnerable to the AVM shunting of HHT and the
extrahepatic ducts with multiple extrahepatic blood suppliers -more than seven arteries
including the cystic artery, posterior superior pancreaticoduodenal artery, right hepatic
artery, and retroportal artery-. The conclusion as mentioned by Bauer et al earlier is that
biliary ischemia is likely secondary to intrahepatic vascular shunting due to the AVMs.
Biliary ischemia in the setting of hepatic AVMs is likely a dynamic continuum
with mild manifestation of chronic cholangitis (70-80% of hepatic HHT patients have
some degree of cholestasis (76) and with biliary necrosis at the extreme. Factors that
reduce oxygen delivery to these compromised ducts (anemia, pregnancy, GI bleeding)
will push the continuum to its extreme.
Certainly the occasional onset of biliary necrosis post hepatic artery embolization
(HAE) supports this theory of peribiliary ischemia secondary to AVM shunts. HAE is
functional ligation of the hepatic artery with spiral coils or poly vinyl alcohol particles
initially undertaken as a treatment for high output cardiac failure with the aim of arresting
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flow into the (hepatic artery to hepatic vein) shunt and resolving the high flow state. In
instances of concomitant portal vein to hepatic vein shunts the portal vein cannot supply
the peribiliary plexus or liver parenchyma with sufficient oxygenated blood and biliary
ischemia and necrosis result. In 1998 Odorico et al (77)reported two female patients 47
and 48 years old with biliary ischemia secondary to hepatic artery embolization. Initially
they presented with chronic abdominal pain, weight loss and multiple hepatic AVMs on
CT and angiography, but unlike previous cases, normal liver function tests. Both patients
underwent hepatic artery or branch embolization with temporary relief of pain followed
by onset of RUQ syndrome, sepsis and large biloma formation. In both cases the authors
considered percutaneous or surgical drainage of the collections but deferred for two
reasons: a) bleeding risk and b) the diffuse appearance of multiple bilomas throughout the
presumably necrosed liver parenchyma. In the setting of intrahepatic biliary sepsis and
liver failure both patients underwent successful liver transplant and were alive at 9 and
12-month follow-up. Odorico et al emphasized the deleterious effects of hepatic artery
embolization in these patients with hepatic AVMs (mortality close to 20% in a metaanalysis of the literature) with complications including parenchymal necrosis and liver
failure. A similar outcome was noted by Hillert et al (2001) (78) in a 39 year-old gravid
woman with diffuse abdominal pain during her second pregnancy necessitating cesarean
section at 29 weeks for non-reassuring cardiotocogram. The patient went on to develop
persistent pain post delivery, hemobilia, and an uncontrollable upper GI bleed and
underwent a Billroth resection (pylorectomy with end to end anastomosis of the
remaining stomach with the duodenum), ERCP and hepatic artery embolization and
then deterioration of liver function and sepsis necessitating transplant. The explant had
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multiple bilateral cystic lesions characteristic of diffuse purulent and chronic cholangitis
with post-infectious cystic dilations, necrosis of mucosa of small and large bile ducts and
destruction of most of the parenchyma (not unlike what Blewitt et al (53) later described
spontaneous biliary ischemia secondary to HAVM, telangiectases rupture and liver cell
“disintegration”).
With hepatic artery embolization or ligation (79, 80), blood flow within the
peribiliary plexus is even more compromised. The effect of transarterial embolization had
also been documented in HCC patients where the vessels in the peribiliary plexus are lost
or show coagulation necrosis adjacent to or within the necrotic bile ducts (61). These
cases of post-HAE biliary ischemia are analogous to our cases of spontaneous biliary
ischemia in setting of AVM shunts (“poverty amidst plenty”) and to the sequelae of
hepatic artery thrombosis post liver transplant where clinical presentation consists of
fulminant hepatic necrosis, bile leak or relapsing bacteremia/septicemia (81, 82).
Zajko et al (1987) (83) present post-liver transplant patients who developed
biliary strictures, both intra and extra hepatic, after hepatic artery occlusion (14/31
patients). 3 of the 14 developed bilomas. 4 of the 14 presented with biliary obstruction
symptoms leading to imaging and the remaining 9 were known to have the HA occlusion
prior to discovery of the strictures (early diagnosis). Strictures are described as
anastamotic and nonanastamotic with the latter more likely due to ischemia and the
former to scar formation and retraction. They are the result of under or arrested perfusion
of the peribiliary plexus effectively severing the end arterial supply. In sever ischemia at
the time of transplantation (or in response to inflammation of the biliary tract), necrosis
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results and bile leaks can be seen. In most of these cases Zajko et al preformed
percutaneous drainage until liver re-transplant was possible.
Biliary ischemia and necrosis also occurs as a spectrum of focal to diffuse
depending on the anatomy of the vascular malformations and the resultant interruption of
blood flow and oxygenation. Boillot et al in 1999 (84) presented a case of a 36-year-old
gravid woman with marked diffuse hepatic necrosis and abscesses following
cholecystectomy, ERCP and cesarean section who ultimately received a liver transplant
as there was no other way to treat the disseminated hepatic sepsis secondary to
superinfection.
In the same year Chen et al (1999) (69) reported a 26-year-old female
patient with protracted RUQ pain, fever and jaundice, an elevated alkaline
phosphatase 7 times the upper limit of normal and a focal biloma on imaging.
ERCP was done and revealed normal sized intrahepatic ducts with some
extravasation at the right hepatic ducts. They deferred percutaneous drainage for
fear of bleeding risk but they did intervene surgically with an open laparotomy,
cyst aspiration, hepatic artery ligation and liver biopsy. This was done prior to the
shift in thinking regarding the risk-benefit imbalance of HAE. Initially the biloma
was sterile and small but likely became infected and progressed in size with
instrumentation. The patient died at an outside hospital ultimately of an unknown
cause but with evidence of biloma progression 11 months prior to death. While
Chen at el, agreeing with Bauer (73) and Mendoza (72), support the theory that the
biloma was related to bile duct ischemia, they do not attribute RUQ pain to the
biloma as it was not large enough to have an expansive effect on the liver capsule,
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also when it later recurred post hepatic artery ligation the patient did not complain
of pain. They do conclude with a recommendation for ERCP or percutaneous
drainage for this focal presentation and certainly we know now that percutaneous
drainage when possible is optimal but that ERCP has led to various degrees of
biliary ischemia exacerbation. Later in 2006, Klepchick et al (85) reported another
case of focal biliary ischemia in a 31 year-old woman with RUQ pain, diagnosed
with biliary dyskinesia who underwent cholecystectomy and returned with pain
and fever, alkaline phosphatase 7 times the upper limit of normal and collections
later found to be focal groups of dilated bile ducts. As with our patient
interventional radiology was asked to drain the collections, found to be sterile,
reduced in size and then followed by pain recurrence. The pattern of focal
segmental bile duct dilatation led the authors to suggest a “Caroli’s variant” as an
etiology for the biliary presentation in this HHT liver.
Azoulay et al in 2002 (86) from France reported 3 female patients, 38, 49 and 38years-old (2 of them sisters) with repeated episodes of cholangitis and abdominal pain,
with alkaline phosphatase abnormalities in the 200-300 range. The two sisters underwent
cholecystectomy and both developed abscesses post-op that required repeated drainage.
Ultimately the three patients received liver transplant (the quick move to treat these
biliary patients with liver transplant maybe because the authors were reporting from a
hepatobiliary and liver transplant unit). The authors propose that nodular transformation
(described by Wanless at al 1986 (44) have described nodular transformation as a variant
of nodular regenerative hyperplasia secondary to abnormal blood flow), fibrosis and
biliary ischemia induced by the AV malformations. They suggest nodular transformation
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can cause compression or stricture of large bile ducts favoring stasis, infection and
lithiasis (as described by Ball (71) and Mendoza (72)).
Yet another theory proposed by Hatzidakis et al (2002) (87) is that of “external”
or mechanical compression of bile ducts. The authors propose external vascular
compression by the hepatic AVMs on the bile ducts, based on anatomical proximity on
imaging, as a cause for their focal dilatation. Similar mechanical rather than
ischemic/fibrotic etiology is ascribed to biliary obstruction in extrahepatic portal
hypertension caused by periportal varices by compressing the extrahepatic bile ducts.

Yale experience with liver HHT Type 3

The Garcia-Tsao et al paper in 2000 (42) on Liver involvement and HHT based
on the Yale-HHT experience was the first paper to highlight a large number of HHT liver
patients 5/19 with biliary sequelae, 2 of those with right upper quadrant pain as their
initial presentation as well as alkaline phosphatase abnormalities. All 5 patients had
alkaline phosphatase abnormalities and bile duct pathology on imaging similar to Caroli’s
disease and sclerosing cholangitis. Garcia refers to the latter as secondary sclerosing
cholangitis and attributes the development of biliary strictures (a process described with
hepatic artery instillation of chemotherapeutic drugs (88) as well as post-liver transplant
(83) which induces the formation of bile collections/cysts/bilomas directly to the bile duct
ischemia caused by the AV shunting. Garcia further suggests vascular malformations at
the ductal plate (Caroli-like) could contribute to abnormal biliary duct system
development. Caroli’s variant is a congenital disorder of insufficient reabsorption of
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ductal plates resulting in multifocal segmental dilatation of large intrahepatic bile ducts.
A retrospective review of liver biopsy histology from these 5 patients with respect to the
following features revealed: ectatic vessels in 4; periductal fibrosis in 3 and bile-duct
necrosis in 1 (versus none in the portal hypertension group); sinusoidal fibrosis in 0
(versus most in the portal hypertension group); nodularity, absent in 1, nodular
hyperplasia (regeneration alternating with atrophy) in 3, true cirrhosis in 1; fibrosis along
ecstatic vessels in 2. The histology reflects predominant shunts in either patient subgroup;
hepatic artery to hepatic vein +/- portal vein and resultant relative ischemia of the
peribiliary plexus versus hepatic artery to portal vein shunts and resultant increase in
resistive indices in sinusoids and post sinusoids, increased flow with adjacent relative
(and chronic) ischemia leading to atrophy adjacent to hyperplasia, nodular hyperplasia
and portal hypertension.
A paper that changed our thinking about pathophysiology of HHT of the liver was
published in 2003 (53). Blewitt et al described a 34-year-old patient with RUQ pain,
normal liver function tests initially with only mild rise in AP to upper limit of normal.
The patient underwent cholecystectomy and liver biopsy. Post-op minor acoustic changes
were seen on ultrasound followed by development of definite cystic changes and an
alkaline phosphatase 13 times the upper limit of normal. The patient ultimately received a
liver transplant and did very well. The authors agreed with Bauer (73)and McInroy (75)
who suggested biliary necrosis of bile ducts due to AV shunting may lead to liver damage
(all three of these cases started with some form of biliary inflammation) but also offer an
explanation for hepatic disruption based on histology, proposing rupture of the periportal
telangiectases as the precursor step to bile duct necrosis. Periportal telangiectases are
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delicate, susceptible to rupture as they get larger and if they coalesce as they rupture they
could dissect into the liver parenchyma, accentuate AV shunting by changing the
dynamics of flow and cause ischemic insult to hepatocytes and bile ducts leaving other
telangiectases without hepatocyte support, liable to rupture and so on. Effectively the
liver cells “fall apart” in what they dub “disintegration”. Blewitt et al suggest in addition
that these AVMS create localized shunt areas of high flow and high pressure leading to a
relative ischemia that causes in turn atrophy of liver cell plates, a drop in mechanical
portal canal support, decreasing support for telangiectatic vessels that then become more
fragile and liable to rupture into the liver parenchyma; a process of hepatic collapse,
labeled by the authors “hepatic disintegration”. The micrographs presented in Blewitt et
al show liver cells falling apart as a result of telangiectatic rupture/hemorrhage and likely
relative ischemia, probably just short of necrosis. While the hemorrhages in the
micrographs appear real it is difficult to see the break in the vessel wall since they are
usually very thin and when they bleed the liver tissue is covered in blood. Dr. GarciaTsao suggests that an elastic tissue stain or trichrome stain could show the vessel wall
and the breaks within the wall, however these were not shown in the Blewitt paper.

Pregnancy in the Type 3 liver HHT patient
A number of case reports relate to the exacerbation of hepatic vascular shunt
sequelae in gravid HHT patients (78, 84) likely linked to the expansion of circulatory
volume. Cardiac output in pregnancy increases 30-50% initially due to an increase in
stroke volume (SV) and subsequently due to a rise in heart rate (HR) of about 10bpm.
Most of the increase in cardiac output (CO) occurs before 20 weeks though it continues
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into the third trimester and plateaus at 32 weeks. The increase in oxygen consumption
occurs mostly in the second half of pregnancy reaching 20-30% above the non-gravid
state at term. There is also an increase in blood volume to 45% of non-gravid women.
The expansion of plasma volume precedes that of red cell volume creating a dilutional
effect but the rise in hemoglobin and CO compensates for the rise in oxygen requirement.
Pregnancy itself may also increase the AVM chance of bleeding secondary to estrogen
effect on vascular fragility, although the exact mode of action of sex hormones and their
role is unclear. In a double blind RCT 50ug ethinylestradiol and 1mg norethisterone
resulted in significant reduction of transfusion requirements for HHT patients (89). The
exact mechanism remains unclear however and keeping in mind that HHT patients are at
risk for thromboembolic disease these hormonal agents must be used with caution.

Treatment
The Yale-HHT experience with Type 3 hepatic involvement illustrates the
unpredictable and non-linear clinical course as well as the dilemma in management.
To our knowledge this is the first case report of patients (two sisters) with localized
biliary ischemia in the setting of hepatic AVMs and remission with percutaneous
drainage. While it is difficult to identify sentinel signs that differentiate their clinical
picture from that of those with more diffuse biliary ischemia it is clear that these two
patients benefited from the conservative approach to their management. The description
of hepatic disintegration by Blewitt et al, and possibly the cause of death in our P__ led
us to proceed very carefully with P1 and 2. Refractory RUQ pain, elevated alkaline
phosphatase to 3x upper limit of normal and hemodynamic parameters (HR and BP)
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within normal range set these patients apart from the Type 1 to Type 3 converters but did
not help differentiate them from the Type 3s with diffuse ischemia.
Certainly conservative/medical/goal directed-symptom relief is always the first
step. Eliminating the hepatic AVM’s feeding artery has been attempted via hepatic artery
ligation (90-92) or embolization (93-97) with varying degrees of success and failure. The
US HHT community decidedly moved away from these procedures in 2000 given the
unpredictable complication profile. While hepatic artery ligation is invasive and less
selective in its blockade (with embolization one can eliminate selective smaller
branches). Embolization is associated with a number of complications from reflux of the
embolization material outside the target area, to total ischemia to the area and
necrosis/infarct of parenchymal tissue. Adverse outcomes include abdominal pain,
gastrointestinal bleeding, abscesses, biliary ischemia, acute liver failure requiring
emergency liver transplantation and death. For the 24 cases reported overall morbidity
was 42% and overall mortality 17% (42, 77, 79, 92-95, 97-103). Revascularization and
AVM recurrence have also been documented post HE (92). In Europe hepatic artery
embolization remains a treatment option but admittedly done with caution and at centers
with transplant capabilities should they be needed. The most likely explanation for this
wide range of response to the embolization reflects the diversity of vascular malformation
configurations within the HHT liver. Whiting et al explain that patients with hepatic
artery to hepatic vein communications may tolerate embolization better than patients in
whom there are also portal vein to hepatic vein communications given that in the setting
of AVMs the portal vein is likely only to hypoperfuse the liver. The authors exclude
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partial hepatectomy or lobectomy as an option given the extensive vascular network
precludes safe surgical resection.
That said, currently the treatment for severe liver involvement (as well as post HE
complications), intractable heart failure, severe portal hypertension, refractory ascites and
acute diffuse biliary necrosis is liver transplantation. Many HHT patients will not be
eligible given their age or co-morbidities (diffuse PAVMs for example) in which case a
risk-benefit analysis should guide the clinician with regard to treatment course.

Conclusion
If these patients with symptomatic hepatic HHT type 3 are identified early in the
course of the disease, monitored carefully and cautiously avoiding any invasive liver
procedures especially when presenting with abdominal pain and/or alkaline phosphatase
abnormalities and bile leaks on imaging, it may be possible to stave off the need for the
extreme intervention of liver transplant. The HHT community has decidedly moved away
from hepatic artery embolization and ligation given the evidence that these procedures
can exacerbate biliary ischemia and hepatic failure (77, 92). Although the literature
remains divided with some groups presenting prospective on embolization with good
outcome. Chavan et al (104) present the largest such series, 15 patients treated with
staged hepatic artery embolization with good outcome; 5/5 patients with abdominal pain
relieved and 10/11 with increased cardiac output and/or cardiac failure improved (from
around 12 to 8). They do suggest that patients with preexistent cirrhosis be excluded (this
patient in their series died).
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The Type 3 patient’s symptoms (RUQ pain, fever, jaundice) will often remit
spontaneously or with correction of anemia, termination of pregnancy, etc. We have
documented the first case of localized biliary ischemia in a HHT patient with Type 3 liver
involvement and conclude that avoiding invasive procedures but pursuing percutaneous
draining of symptomatic bile leaks seen on imaging maybe be life saving. These patients
need to be monitored closely in coordination with a transplant center in the event that
percutaneous drainage fails and/or hepatic failure is inevitable. That said appropriate
transplant guidelines for these patients need to be developed by the global HHT
community to protect them in cases of slipping along the biliary ischemia continuum
towards biliary necrosis, although many of these patients concomitantly have diffuse
PAVMs that would preclude them from transplant. Some advances have been made in
this area, Garcia-Tsao et al in 2006 suggested a MELD (model for end stage liver
disease) exception for HHT patients. While the authors found insufficient objective
evidence to grant HHT patients with/nearing liver failure automatic priority they did
propose priority be assigned based on a case by case review by the regional review board
where a score of 40 is given to patients with acute biliary necrosis and a score of 22 to
patients with medically refractory heart failure and an addition of 10% mortality risk to
the score 3 month interval review (105). Overall the medical community is recognizing
the spectrum of visceral HHT involvement and the need for preventive care, screening
when appropriate and cautious management.
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Figure 1:

Normal liver (modified from Garcia-Tsao 2007, presentation) to compare
with 3 types of shunts in HHT liver presented on the following pages.
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Figure 1a:

Diagram of hepatic artery to hepatic vein shunt (modified from GarciaTsao 2007, presentation). When this shunt predominates sequelae can
include high output cardiac failure and biliary ischemia.
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Figure 1b:

Diagram of hepatic artery to portal vein shunt (modified from GarciaTsao 2007, presentation). When this shunt predominates sequelae can
include liver fibrosis, portal hypertension, varices and splenomegaly.
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Figure 1c:

Diagram of portal vein to hepatic vein shunt (modified from Garcia-Tsao
2007, presentation). When this shunt predominates sequelae can include
hepatic encephalopathy.
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Figure 2a:

Initial abdominal CT at outside hospital in December 2006, 4 months after
onset of RUQ pain.
The liver is hypervascular compatible with HHT, no biloma.
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Figure 2b:

7 months after initial CT and with continued symptoms, abdominal CT
showing new biloma.

Figure 2c:

Repeat abdominal CT 3 days later showing biloma progression.
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Figure 2d:

Percutaneous biliary drainage catheter in place.

Figure 2e:

Contrast injection via biliary drainage catheter demonstrating size of
biloma. With pain control the patient was discharged home.
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Figure 2f:

Cholangiogram 1week post discharge at scheduled follow-up. No interval
change in size of biloma.
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Figure 2g:

5 week follow-up outpatient cholangiogram demonstrating reduction in
size of biloma following drainage.
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Figure 2h:

10 week follow-up demonstrating marked reduction in biloma size.
Concomitantly patient had reduction in biliary drainage and improved
clinically. 4 weeks later catheter was removed when bile drainage was no
longer present, patient was without pain and remains asymptomatic 3
months after removal.
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Figure 3:

Laboratory abnormalities in patient WM with localized biliary ischemia.
X axis: time course (Jan-Sept 2007)
Y axis: absolute value. AST: aspartate aminotransferase; ALT: alanine
amino transferase; Bili: total bilirubin; AlkPhos: alkaline phosphatase;
HD: hospital day.
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TABLE 1: HHT Type 3 patients at Yale: 8 patients.
Age

Sex

Case

Presenting
symptom
RUQ/abd
pain

N/v, wt
loss

Other

Lab
abnormality
AP

Imaging

P1

39

F

y

y

y (269)

Bili>
2.0
mg/d
L
n

P2

31

F

y

y

y (200-400)

n

P3

61

F

y

P4

33

F

y

Back pain,
SOB

y (200-300
then 1530)
y (171 Æ
1127)

P5

42

F

y

SOB

y (200-400)

P6

37

F

y

P7

47

F

y

P8

59

F

y

y

Back pain,
hepatic

Time
course
(onsetoutcome
yrs)

Intervention

Sequelae

Outcome

Localized
biliary
ischemia
Localized
biliary
ischemia

Alive

Urgent perc
drain
Bile salts +
analgesia

Hepatic
infarct
Intrahepatic
hemorrhage

Dead (70)

6a

Bile salts +
analgesia

Hepatic
disintegration
and
hemorrhage

2

Lap chole,
liver bx,
ERCP, bile
salts and
analgesia,
OLT
Liver bx, bile
salts and
analgesia.

Cysts (#)

HA
(mm)

y (1)

na

PAVM

1

Perc drain

y (1)

na

2

Perc drain

y (1)b

5

h/o
episode
while
gravid
Mild HF

c

n

y (1)

10

y
(2.2)

y (multiple)d

13

y (700-1000s)

ye

na

nl until liver
bx (1000s Æ
174
spontaneously
y (200-300)

y (multiple)

11.5

y (1)

na

n

PMH/
Other

HF,
diffuse
severe
PAVM,
and
CAVM
HF,
diffuse
severe
PAVM,
and
CAVM
Marfan’s

9a
17

7

HF

6

a

MRCP,
antibiotics

Alive

Dead (34)

Dead (48)

Dead (38)

Spontaneous
remission

Alive

Spontaneous
remission

Alive

54

encephalop
athy
RUQ: right upper quadrant; Abd pain: abdominal pain; jaun/chol: jaundice/cholangitis; n/v: nausea/vomiting; wt loss: weight loss; AP: alkaline phosphatase; Bili: bilirubin; AVM: arteriovenous
malformation; PAVM: pulmonary arteriovenous malformation; CAVM: cerebral arteriovenous malformation; PMH: past medical history; HF: heart failure; perc: percutaneous; Lap chole: laparoscopic
cholecystectomy; Liver bx: liver biopsy; ERCP: endoscopic retrograde cholangiopancreatography;MRCP: Magnetic resonance cholangiopancreatography.
a P3-P5 are Type 1 to Type 3 converters and had been followed for their HF for many years prior to onset of biliary ischemia. P3 (8/9 yrs type 1), P4 (14/17 yrs type 1) P5 (5/6 yrs type 1). Type 1 to 3
conversion is associated with the highest mortality in our series.
b Also developed an area of hepatic infarct in the anterior segment of the right hepatic lobe.
c Also developed multiple wedge shaped filling defects in the right lobe pole.
d Also developed liver hemorrhage and subcapsular hematoma.
e Also developed intra-hepatic ductular abnormalities with dilated ducts and truncated small tapering ducts.
f Also bile duct dilation
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TABLE 2: HHT Type 3 patients in the world literature: 14 reported cases
Case

Age

Sex

Presenting
symptom
Other
fever
doe,
melena
fever

y (1167)
y (231Æ
1361)
y (671)

Imaging

Ball (1990)71
Bauer (1995)73

62
33

F
F

RUQ/abd
pain
y
y

McInroy
(1998)75
Odorico
(1998)77

31

F

y

48

F

y

y

47

F

y

y

Boillot (1999)84

36

F

ya

Chen (1999)69

26

F

y

fever

Hillert (2001)78

39

F

ya

hemobil
ia

Azoulay
(2002)86

38

F

y (203)

344
um/L

49

F

y (337)

38

F

y (145)

249
um/L
24 um/L

34

F

Blewitt (2003)53

y

N/v, wt
loss
y
y

Lab
abnormalit
y
AP

Bili>2.0
mg/dL
n
n

Biliary
abnl
y
y

y (2.02)

y
y (post
AE)

y (post AE)

y (864)

y (131)

PMH/
Other
*

Biliary
inflam
Biliary
inflam

Time
course
(onsetoutcome)
months
6 (hrs)
8
3
4

Intervention

Abx
Abx, OLT
Abx, ERCP,
liver bx, OLT
AE
(pancreatoduode
nal a.), OLT
ERCP, AE
(hepatic), chole
(gangrenous),
OLT
Chole, c-section
@28wk, OLT

y (post
AE)

2

y

y

5

n

y

15

ERCP, HA
ligation

y

10

C-section
@29wk,
endoscopy and
billroth I, ERCP
and AE
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Sequelae

Chole, ERCP,
perc drain, OLT
Chole, liver bx,

Outcome

Dead
Alive at 24
mo
Alive
Bacteremia
and LFT abnl
post AE
Bacteremia
and LFT abnl
post AE

Alive at 12
mo

Icterus and
hepatic
abscesses post
chole
Bacteremia
post ligation,
biloma
progression
Post HAE: AP
2083, tbili 8.5
Æ 20, bilomas

Alive at 65
mo

Alive at 9
mon

Dead

Alive at 12
mo

Unknown
Unknown
Unknown
Alive at 36
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(2005)
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Klepchick
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fever

n
n

y
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y
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OLT
Chole, OLT
Chole, perc
drain

Post-op AP
499Æ 2212,
Tbili 2.8
Post-op AP
790

mo
Alive at 3 mo
Unknown

RUQ: right upper quadrant; Abd pain: abdominal pain; jaun/chol: jaundice/cholangitis; n/v: nausea/vomiting; wt loss: weight loss; AP: alkaline phosphatase; Bili: bilirubin; AVM: arteriovenous
malformation; PAVM: pulmonary arteriovenous malformation; CAVM: cerebral arteriovenous malformation; PMH: past medical history; HF: heart failure; perc: percutaneous; Lap chole: laparoscopic
cholecystectomy; Liver bx: liver biopsy; ERCP: endoscopic retrograde cholangiopancreatography;MRCP: Magnetic resonance cholangiopancreatography; Abx: antibiotics; AE: arterial embolization;
blank: not mentioned
a Boillot and Hillert report two patients with onset of symptoms during pregnancy.
* no mention of PAVM/CAVM

